Research programme: scanning unnatural protease resistant peptides - EvoRx

Drug Profile

Research programme: scanning unnatural protease resistant peptides - EvoRx

Alternative Names: EVO-004; SUPR 4; SUPR-18F

Latest Information Update: 22 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EvoRx
  • Developer EvoRx; University of Texas M. D. Anderson Cancer Center
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Computer-assisted image interpretation enhancers; Image enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 20 Sep 2013 EvoRx receives SBIR grant from National Cancer Institute for scanning unnatural protease resistant peptides development in Breast Cancer (Diagnsosis)
  • 01 Jan 2013 Preclinical trials in Breast cancer (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top